Clinical Trial Detail

Contact

Missing content? – Request curation!

Request curation for specific Genes, Variants, or PubMed publications.

Have questions, comments, or suggestions? - Let us know!

Email us at : ckbsupport@jax.org

NCT ID NCT03662074
Title Second Line Gemcitabine and Nivolumab in Treating Participants With Metastatic Small Cell Lung Cancer
Recruitment Terminated
Gender both
Phase Phase II
Variant Requirements No
Sponsors Wake Forest University Health Sciences
Indications
Therapies
Age Groups: adult | senior
Covered Countries USA


No variant requirements are available.